A Novel Approach to Partition Central and Peripheral Airway Nitric Oxide
|
|
- Cordelia Bennett
- 6 years ago
- Views:
Transcription
1 CHEST A Novel Approach to Partition Central and Peripheral Airway Nitric Oxide Paolo Paredi, MD, PhD ; Sergei A. Kharitonov, MD, PhD ; Sally Meah, RGN ; Peter J. Barnes, DM, DSc, Master FCCP ; and Omar S. Usmani, MBBS, PhD Original Research ALLERGY AND AIRWAY Background: Determining the site of airways inflammation may lead to the targeting of therapy. Nitric oxide (NO) is a biomarker of airway inflammation and can be measured at multiple exhalation flow rates to allow partitioning into bronchial (large/central airway maximal nitric oxide flux [J aw NO] ) and peripheral (peripheral/small airway/alveolar nitric oxide concentration [C ANO ]) airway contributions by linear regression. This requires a minimum of three exhalations. We developed a simple and practical method to partition NO. Methods: In 29 healthy subjects (FEV 1, 97% 3% predicted), 13 patients with asthma (FEV 1, 90% 4% predicted), 14 patients with COPD (FEV 1, 59% 3% predicted), and 12 patients with cystic fibrosis (CF) (FEV 1, 60% 3% predicted), we measured the area under the curve of the NO concentration/exhalation time plot (AUC-NO) at exhalation flow rates of 50, 100, 200, and 300 ml/s. We determined the change of the total AUC-NO production ( AUC-NO) among the four different exhalation flow rates and compared these levels to C ANO and J aw NO indices measured conventionally by linear regression. Results: The change in AUC-NO between increasing exhalation flow rates of 50 to 200 ml/s ( AUC-NO ) was strongly correlated with J aw NO in all patient groups as follows: healthy subjects ( r , P,.001), patients with asthma ( r , P,.001), patients with COPD ( r , P,.001), and patients with CF ( r , P,.05). In all subjects, AUC-NO at an exhalation flow rate of 200 ml/s (AUC-NO 200 ) correlated with C ANO ( r , P,.01). Conclusions: The bronchial production of NO can be determined by measuring AUC-NO , whereas AUC-NO 200 measures its peripheral concentration. This approach is simple, quick, and does not require sophisticated equipment or mathematical models. CHEST 2014; 145(1): Abbreviations: AUC 5 area under the curve; AUC-NO 5 area under the curve of the nitric oxide concentration/exhalation time plot; C ano 5 peripheral/small airway/alveolar nitric oxide concentration; CF 5 cystic fibrosis; F eno 5 fraction of exhaled nitric oxide; J aw no 5 large/central airway maximal nitric oxide flux; NO 5 nitric oxide; ppb 5 parts per billion Nitric oxide (NO) is a biomarker of airways inflammation and an adjunct in the diagnosis and management of respiratory diseases such as asthma, 1-4 a s approved by the Food and Drug Administration. 5 The single exhalation breath measurement of NO (fraction of exhaled NO [F eno ]) is simple, reproducible, and noninvasive, and most notably, the methodology for Manuscript received April 24, 2013; revision accepted July 8, Affiliations: From the Airways Disease Section, National Heart and Lung Institute, Imperial College London and Royal Brompton Hospital, London, England. Funding/Support: Dr Usmani is a recipient of a UK National Institute for Health Research (NIHR) Career Development Fellowship. This project was supported by the NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton & Harefield NHS Foundation Trust and Imperial College London. its detection has been standardized. 6 Currently, there is immense interest in assessing the predominant site of airways inflammation (peripheral vs central) in various pulmonary diseases, and this may be important in targeting antiinflammatory therapy. 7-9 This interest has encouraged the development of mathematical models to interpret the flow-dependent physiology of NO dynamics, 10,11 and the measurement of exhaled NO at different exhalation flow rates has Correspondence to: Paolo Paredi, MD, PhD, Airways Disease Section, National Heart and Lung Institute, Dovehouse St, London, SW3 6LY, England; p.paredi@imperial.ac.uk 2014 American College of Chest Physicians. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details. DOI: /chest journal.publications.chestnet.org CHEST / 145 / 1 / JANUARY
2 been used to partition peripheral (peripheral/small airway/alveolar NO concentration [C ano]) from central (large/central airway maximal NO flux [J aw no]) airways NO production. The latter technique is based on a two-compartment model, 10 which contrary to the single-compartment model, accounts for the production and contribution of central airways NO, explaining the exhalation flow dependency of this gas. 11 This approach requires a minimum of three exhalation flows, and both J aw no and Cano are calculated by a linear regression analysis. This technique has been used to show elevated J aw no in patients with mild to moderate asthma 10 and C ano in patients with refractory asthma, 12 older healthy subjects, 13 patients with COPD, 14 patients with cystic fibrosis (CF), 15 and patients with scleroderma. 16 We revisited and simplified the method for NO partitioning from the two-compartment model to show that the complicated mathematical equations used in the linear regression method could be replaced with the measurement of the area under the curve (AUC) of the NO concentration/exhalation time plot (AUC-NO) obtained at one slow (50 ml/s) and one fast (200 ml/s) patient exhalation flow. In addition, we compared this new technique with a method described by Condorelli et al, 17 which takes into account the axial back diffusion of bronchial NO into the alveolar space. Patients Materials and Methods Twenty-nine healthy volunteers (20 men; mean age, 38 2 years; FEV 1, 97% 3% predicted) were enrolled in the study ( Table 1 ). We also studied 13 steroid-naive patients with asthma (eight men; mean age, 48 8 years; FEV 1, 90% 4% predicted) whose condition was diagnosed according to American Thoracic Society criteria18 ; 14 patients with COPD (10 men; mean age, 63 2 years; FEV 1, 59% 3% predicted), all ex-smokers with a 20-pack-year smoking history and without a history of allergic disease or reversibility of airflow obstruction (. 15% or. 200 ml after 400 mg salbutamol through a metered-dose inhaler); and 12 patients with CF (eight men; mean age, 21 4 years; FEV 1, 60% 3% predicted). The study was approved by the local research ethics committee (reference number 08/H0709/2). Patients with a respiratory tract infection or respiratory disease exacerbation were excluded from the study. Active and passive smokers (exposure for. 0.5 h/d) were excluded. Exhaled NO Measurement Multiple Flows Linear Regression Method: Exhaled NO concentrations were measured by a chemiluminescence analyzer (NIOX; Aerocrine) at expiratory flow rates of 50, 100, 200, and 300 ml/s by applying resistances of 50, 100, 200, and 300 cm H 2 O/mL/s to maintain the target exhalation flow rates. Patients inhaled NO-free air and exhaled through a fixed flow restriction to increase pressure in the mouth up to 10 cm H 2 O, which is effective in closing the soft palate and isolating the nasopharynx. Dead space air was excluded from the analysis. The analyzer was calibrated with a known NO concentration (200 parts/million). Every subject performed two exhalations at each exhalation flow. The bronchial production of NO (J aw no ) and its alveolar concentration (C ano ) were calculated by linear regression according to the equation of Tsoukias and George, 10 where the slope and the intercept of the regression line between NO output and exhalation flow indicates C ano and J awno, respectively. In addition, J aw no and C ano were also calculated using the Condorelli adjustment for the axial diffusion of NO as follows 17 : J aw no ( I ) and C ano 5 [( S ) 2 (I )]/(740 ml/s), where S is the slope and I is the y-intercept by simple linear regression. Dual Flows Measurement by AUC Method: The database containing the measurements of C ano and J aw no calculated by the linear regression method was downloaded from the NO analyzer and transferred to a computer. For each expiratory flow rate (50, 100, 200, and 300 ml/s), the point-by-point values of the NO concentrations were plotted graphically against the exhalation time (up to 10 s) ( Fig 1 ). The AUC-NO was calculated by the average of two measurements at each expiratory flow rate with Prism version 5.03 (GraphPad Software, Inc) ( Fig 1 ). The software calculated the AUC by the trapezoidal method. This process was straightforward and took, 1 min to compute. We then studied the change in the AUC-NO between increasing exhalation flow rates of 50 to 100 ml/s ( DAUC-NO ), 50 to 200 ml/s ( DAUC-NO ), and 50 to 300 ml/s ( DAUC-NO ). We compared the average AUC-NO values with the J aw no and C ano values calculated by conventional linear regression and with values calculated by the Condorelli adjustment method with the same data as described previously. Lung Function Tests All patients underwent pulmonary function testing. Testing included spirometry and lung volumes by body plethysmography (Jaeger Master Laboratory Compact Transfer; Erich Jaeger Ltd). Statistical Analysis Comparisons between patient groups were made by one-way analysis of variance with Bonferroni correction. Kruskal-Wallis one-way analysis of variance was used to analyze nonparametric data. Correlations are presented as nonparametric Spearman rank correlation coefficients. Data were expressed as mean SEM and CIs of differences. Significance was defined as P,.05. Agreement between methods was confirmed with Bland-Altman plots. Results Single-Breath F ENO and Linear Regression Method F eno was significantly elevated in patients with asthma ( parts per billion [ppb], P,.01), whereas it was significantly reduced in patients with CF ( ppb, P,.01) compared with healthy subjects ( ppb). Patients with COPD ( ppb) had similar levels to those of the healthy subjects ( Fig 2A ). J aw no was significantly elevated in patients with asthma ( ng/s, P,.01) but significantly reduced in patients with CF ( ng/s, P,.05) compared with healthy subjects ( ng/s). Patients with COPD had comparable values to the healthy subjects ( ng/s, P..05) (Fig 2B ). 114 Original Research
3 Table 1 Patient Characteristics Characteristic Asthma (n 5 13) COPD (n 5 14) CF (n 5 12) Healthy Subjects (n 5 29) Age, y Male (female) sex 8 (5) 10 (4) 8 (4) 20 (9) FEV 1, % predicted F eno, ppb J aw no, ng/s a b C ano, ppb a b a J aw no /DAUC-NO correlation C ano /AUC200 correlation Data are presented as mean SEM or R 2 unless otherwise indicated. AUC area under the curve of the nitric oxide concentration/exhalation time plot at a high exhalation flow rate of 200 ml/s; AUC-NO area under the curve of the nitric oxide concentration/exhala tion time plot between exhalation flow rates of 50 to 200 ml/s; C ano 5 peripheral/small airway/alveolar nitric oxide concentration; CF 5 cystic fibrosis; F eno 5 fraction of exhaled nitric oxide; J aw no 5 large/central airway maximal nitric oxide flux; ppb 5 parts per billion. a P,.01. b P,.05. Similarly, Cano was significantly higher in patients with asthma ( ppb, P,.01) and significantly lower in patients with CF ( ppb, P 5.01) compared with healthy subjects ( ppb). However, in contrast to the J aw no results, C ano was significantly elevated in patients with COPD ( ppb, P,.05) (Fig 2C ). Dual Flow Rates Measurement With AUC Method Patients with asthma consistently showed significantly elevated AUC-NO values at every exhalation flow rate (50, 100, 200, and 300 ml/s) compared with healthy subjects, whereas patients with CF had significantly lower AUC-NO values at all exhalation flow rates ( Fig 3 ). The AUC-NO values of the patients with COPD were similar to those of healthy subjects at 50, 100, and 200 ml/s but were significantly higher at exhalation flow rates of 300 ml/s. There was far greater variability in the AUC-NO measurements for patients with asthma compared with the other groups. An exhalation flow rate dependency of AUC-NO was observed in all groups, especially in patients with asthma, who had the greatest fall in the AUC-NO values with increasing exhalation flows compared with all other groups ( Figs 3, 4 ). The decrease in AUC-NO in patients with CF was significantly lower than in healthy subjects, whereas patients with COPD had a similar magnitude of AUC-NO change to healthy subjects ( Fig 4 ). Additionally, the observation of the fall in AUC-NO was also consistent among all exhalation flow comparisons ( D AUC-NO , D AUC-NO , and DAUC-NO ) in all groups. J aw NO Agreement With AUC-NO AUC-NO was significantly correlated with J aw no as measured by linear regression in healthy subjects ( r , P,.001) ( Table 1 ), patients with asthma ( R , P,.001), patients with COPD ( R , P,.001), and patients with CF ( R , P,.001 ). These agreements were also confirmed by Bland-Altman plot 17 ( Fig 5A ). The same strong correlations between J aw no and D AUC-NO were consistent after J aw no correction for axial diffusion of NO. 17 Figure 1. A, Exhaled NO/time tracings at flow rates of 50 ml/s in healthy subjects and all study groups. B, An example of the AUCs calculated at flow rates of 50 and 200 ml/s to provide AUC AUC 5 area under the curve; AUC change in the area under the curve between increasing exhalation flow rates of 50 to 200 ml/s; CF 5 cystic fibrosis; NO 5 nitric oxide; ppb 5 parts per billion. journal.publications.chestnet.org CHEST / 145 / 1 / JANUARY
4 Figure 2. A-C, F E NO levels (A), bronchial production (J awno) (B), and alveolar concentrations (CANO) (C) in healthy subjects ( ) and patients with COPD ( ), CF ( ), and asthma ( ). CANO 5 peripheral/small airway/alveolar nitric oxide concentration; F E NO 5 fraction of exhaled nitric oxide; J awno 5 large/central airway maximal nitric oxide flux. See Figure 1 legend for expansion of other abbreviations. C ANO Agreement With AUC-NO Not surprising, DAUC-NO was not significantly correlated with C ano in any of the study groups except in the patients with asthma, where a positive correlation was observed ( R , P,.05). However, AUC-NO at a high exhalation flow rate of 200 ml/s (AUC-NO 200 ) was significantly correlated with C ano measured by linear regression in patients with asthma ( R , P,.001) and COPD ( R , P,.05). The same strong correlations between C ano and AUC-NO 200 were consistent after correction for axial diffusion of NO 17 ( R [ P,.001] vs r [ P,.01] in patients with asthma vs COPD, respectively) and for all the subjects together ( R , P,.01). This agreement was confirmed by Bland-Altman plot (Fig 5B ). Reproducibility of AUC-NO The difference in the AUC-NO values measured during two successive exhalations (n 5 15) at 5-min intervals (single-session variability) was 5.4%, whereas the between-session variability (n 5 16) at a 1-day interval was 6.8%. The reproducibility of the test was confirmed by Bland-Altman plot. 22 Discussion This study shows that the bronchial production of NO and its alveolar concentration can be calculated by a novel method that measures the changes in AUC-NO values resulting from exhalations at slow and fast flow rates. The results agree with J aw no and C ano estimated conventionally by a linear regression equation. The advantage of the present method is that it does not require sophisticated calculations and specific software and may allow wider application of these measurements within the academic community. NO is a promising noninvasive biomarker of airway inflammation for many pulmonary conditions. 1,2,4 NO Figure 3. AUC-NO shown at increasing exhalation flow rates (50, 100, 200, and 300 ml/s) in healthy subjects ( ) and in patients with COPD ( ), CF ( l ), and asthma ( ). * P,.05; ** P,.01. AUC-NO 5 area under the curve of the nitric oxide concentration/exhalation time plot. See Figure 1 legend for expansion of other abbreviations. Figure 4. DAUC in healthy subjects ( ) and patients with COPD ( ), CF ( ), and asthma ( ). See Figure 1 legend for expansion of abbreviations. 116 Original Research
5 Figure 5. A, Bland-Altman plot showing agreement between the bronchial production of nitric oxide (J awno) and the AUC method ( DAUC-NO ). B, The agreement between CANO and AUC-NO AUC-NO change in the AUC-NO between increasing exhalation flow rates of 50 to 200 ml/s; AUC-NO AUC-NO at a high exhalation flow rate of 200 ml/s. See Figure 1, 2, and 3 legends for expansion of other abbreviations. exhibits flow-rate dependency such that it can be partitioned into that produced from peripheral (C ano ) and central (J aw no ) airways, allowing identification of where in the pulmonary tree the inflammation is more active 11 in various pulmonary disorders. 12,23-26 Thus, models to interpret NO dynamics have been developed. The one-compartment model took into account only the lung periphery as a source of NO 27 without explaining the exhalation flow dependency of exhaled NO. 28,29 On the contrary, the two-compartment model acknowledged the central airways as a source of NO. 10 Because the two-compartment technique is the most used model, it is considered by most as the gold standard and was chosen for comparison in the current study. However, this model oversimplifies the human lung by describing the millions of alveoli and respiratory bronchioles as a single huge alveolus and the branching bronchial tree as a single rigid tube. 10 This oversimplification assumes that NO parameters are not affected by lung volume changes during the respiratory cycle. In addition, even if the possible error related to NO axial diffusion has been addressed and the technique has been previously simplified, 17 the violation of the linearity condition, particularly at lower expiratory flow rates, has been shown to cause an overestimation of C ano and an underestimation of J aw no in children, 30 contributing to the reluctance to use NO clinically. 31,32 We developed a simplified method that requires only two patient exhalations and the calculation of the AUC of the respective NO concentration/time tracings, and we compared these results with the J aw no and C ano obtained by linear regression equation.10 The measurement of AUC-NO requires only two pairs of exhalations at 50 and 200 ml/s for a total of four measurements, whereas the conventional linear regression requires at least three exhalations at three different flows, totaling nine measurements. This halves the time required to complete the test. Because the present method is based on the direct analysis of the AUC-NO tracings, it is not limited by the assumptions that characterize the mathematical models described previously. 16 In keeping with previous reports, we observed that F eno was elevated in patients with asthma 33 and reduced in patients with CF 34 compared with healthy control subjects. In patients with COPD, F eno is more controversial 35 and was confirmed not to be elevated in the current study. The partitioning of peripheral and bronchial NO was also consistent with previous publications that showed elevated J aw no in patients with asthma 36 and C ano in patients with COPD. 14 Previous studies in patients with CF produced inconsistent results. We found both C ano and J aw no to be reduced in the present CF cohort compared with healthy subjects, which is consistent with a defect in inducible NO synthase expression in CF. 37 AUC-NO levels were elevated in patients with asthma and reduced in patients with CF compared with healthy subjects at every exhalation flow. Patients with COPD showed similar AUC-NO levels to healthy subjects. These results are in keeping with the F eno levels measured in this study because AUC-NO reflects mostly central airway production. With increasing exhalation flows, we noted a progressive decrease in AUC-NO levels in all study groups, but the extent of the reduction in the AUC-NO values among the different exhalation flows was significantly greater in patients with asthma. In contrast, the change in AUC-NO levels with successively increasing exhalation flows was the lowest in patients with CF, whereas healthy subjects and patients with COPD demonstrated a similar extent of change in AUC-NO levels journal.publications.chestnet.org CHEST / 145 / 1 / JANUARY
6 among the different exhalation flows. Because these changes can be affected by the NO output in the conductive airways, the results may be interpreted as a reflection of increased NO production in patients with asthma in contrast to patients with CF. This implication is confirmed by the strong correlation in all subject groups between DAUC-NO and the conventionally calculated J aw no. In contrast to the other study groups, patients with asthma showed a significant, albeit weaker, correlation between DAUC-NO and C ano, and this may have resulted from a greater axial diffusion of higher bronchial NO production in asthma. We also observed that AUC-NO 200 correlated with C ano measured with the linear regression method. Although we acknowledge that the correlation between C ano and AUC-NO 200 was weaker, it was still highly significant, particularly in asthma ( P,.001). When exhaled at high flow rates, NO levels are derived mostly from the lung periphery because alveolar air has little time to be conditioned by NO produced in the central airways, whereas at lower exhalation flow rates, there is more time for NO to condition alveolar air, and the final NO levels may reflect NO produced more proximally in the bronchi. Therefore, we propose that to partition the bronchial and peripheral component of NO, only a slow (50 ml/s) and a fast (200 ml/s) exhalation flow are required. The DAUC-NO will reflect the bronchial production of NO as it correlates with J aw no, whereas the absolute AUC-NO 200 will reflect peripheral NO concentrations as they correlate with C ano. Conclusions This simpler and more patient-friendly method for the partitioning of exhaled NO can be applied in different groups of patients with pulmonary disease. The direct point-by-point measurement takes into account parallel compartments and sequential filling of the alveoli, potentially reducing the limitations associated with the conventional method. Further studies may support the growing evidence that the partitioning of exhaled NO may complement the measurement of total F eno. Clinical studies investigating the AUC in patients with different degrees of airway obstruction are also required, and we believe that the use of the present method will simplify these studies. Acknowledgments Author contributions: Dr Paredi had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Dr Paredi: contributed to the study design; data analysis; and writing, editing, and final approval of the manuscript. Dr Kharitonov: contributed to the study concept and design and writing, editing, and final approval of the manuscript. Ms Meah: contributed to the study design, recruitment of patients, NO measurements, and reading and final approval of the manuscript. Dr Barnes: contributed to the study concept and design and writing, editing, and final approval of the manuscript. Dr Usmani: contributed to the study design and supervision, data analysis, and writing and final approval of the manuscript. Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Usmani has received honoraria related to advisory board membership (Zentiva Group, Aerocrine), consultancy (Takeda Pharmaceutical Company Limited, Novartis Corporation, GlaxoSmithKline, Pieris AG), and lectures (Takeda Pharmaceutical Company Limited, Chiesi Ltd) and is involved in research for which his university has received industry grant funding (Prosonix Ltd, AstraZeneca, Takeda Pharmaceutical Company Limited, Chiesi Ltd). Drs Paredi, Kharitonov, and Barnes and Ms Meah have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article. Role of sponsors: The sponsors had no role in the design of the study, the collection and analysis of the data, or the preparation of the manuscript. References 1. Barnes PJ, Dweik RA, Gelb AF, et al. Exhaled nitric oxide in pulmonary diseases: a comprehensive review. Chest ; 138 (3): Lim KG, Mottram C. The use of fraction of exhaled nitric oxide in pulmonary practice. Chest ;133(5): Malerba M, Ragnoli B, Radaeli A, Tantucci C. Usefulness of exhaled nitric oxide and sputum eosinophils in the long-term control of eosinophilic asthma. Chest ;134(4): Paredi P, Kharitonov SA, Barnes PJ. Analysis of expired air for oxidation products. Am J Respir Crit Care Med ; 166(12 pt 2):S31-S Silkoff PE, Carlson M, Bourke T, Katial R, Ogren E, Szefler SJ. The Aerocrine exhaled nitric oxide monitoring system NIOX is cleared by the US Food and Drug Administration for monitoring therapy in asthma. J Allergy Clin Immunol ; 114 (5): American Thoracic Society ; European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, Am J Respir Crit Care Med ;171(8): Usmani OS, Barnes PJ. Assessing and treating small airways disease in asthma and chronic obstructive pulmonary disease. Ann Med ;44(2): Usmani OS. Treating the small airways. Respiration ; 84 (6): Anderson WJ, Short PM, Williamson PA, Lipworth BJ. Inhaled corticosteroid dose response using domiciliary exhaled nitric oxide in persistent asthma: the F eno type trial. Chest ; 142 (6): Tsoukias NM, George SC. A two-compartment model of pulmonary nitric oxide exchange dynamics. J Appl Physiol ;85(2): Lehtimäki L, Turjanmaa V, Kankaanranta H, Saarelainen S, Hahtola P, Moilanen E. Increased bronchial nitric oxide production in patients with asthma measured with a novel method of different exhalation flow rates. Ann Med ;32(6): Berry M, Hargadon B, Morgan A, et al. Alveolar nitric oxide in adults with asthma: evidence of distal lung inflammation in refractory asthma. Eur Respir J ;25(6): Original Research
7 13. Gelb AF, George SC, Camacho F, Fraser C, Flynn Taylor C, Shakkottai S. Increased nitric oxide concentrations in the small airway of older normal subjects. Chest ;139 (2 ): Brindicci C, Ito K, Resta O, Pride NB, Barnes PJ, Kharitonov SA. Exhaled nitric oxide from lung periphery is increased in COPD. Eur Respir J ;26 (1 ): Suri R, Paraskakis E, Bush A. Alveolar, but not bronchial nitric oxide production is elevated in cystic fibrosis. Pediatr Pulmonol ;42 (12 ): Tiev KP, Hua-Huy T, Kettaneh A, et al. Alveolar concentration of nitric oxide predicts pulmonary function deterioration in scleroderma. Thorax ;67 (2 ): Condorelli P, Shin HW, Aledia AS, Silkoff PE, George SC. A simple technique to characterize proximal and peripheral nitric oxide exchange using constant flow exhalations and an axial diffusion model. J Appl Physiol ;102 (1 ): Statement on standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis ;136 (1 ): Kharitonov SA, Barnes PJ. Nasal contribution to exhaled nitric oxide during exhalation against resistance or during breath holding. Thorax ;52 (6 ): Paredi P, Loukides S, Ward S, et al. Exhalation flow and pressure-controlled reservoir collection of exhaled nitric oxide for remote and delayed analysis. Thorax ;53 (9 ): Paredi P, Kharitonov SA, Barnes PJ. Direct methods for the measurement of nitric oxide. Monaldi Arch Chest Dis ; 56 (1 ): Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet ;1 (8476 ): van Veen IH, Sterk PJ, Schot R, Gauw SA, Rabe KF, Bel EH. Alveolar nitric oxide versus measures of peripheral airway dysfunction in severe asthma. Eur Respir J ;27 (5 ): Lehtimäki L, Kankaanranta H, Saarelainen S, et al. Extended exhaled NO measurement differentiates between alveolar and bronchial inflammation. Am J Respir Crit Care Med ;163 (7 ): Gelb AF, Flynn Taylor C, Krishnan A, et al. Central and peripheral airway sites of nitric oxide gas exchange in COPD. Chest ;137 (3 ): Foresi A, Leone C, Olivieri D, Cremona G. Alveolar-derived exhaled nitric oxide is reduced in obstructive sleep apnea syndrome. Chest ;132 (3 ): Hyde RW, Geigel EJ, Olszowka AJ, et al. Determination of production of nitric oxide by lower airways of humans theory. J Appl Physiol ;82 (4 ): Högman M, Strömberg S, Schedin U, Frostell C, Hedenstierna G, Gustafsson LE. Nitric oxide from the human respiratory tract efficiently quantified by standardized single breath measurements. Acta Physiol Scand ;159 (4 ): Silkoff PE, McClean PA, Slutsky AS, et al. Marked flowdependence of exhaled nitric oxide using a new technique to exclude nasal nitric oxide. Am J Respir Crit Care Med ; 155 (1 ): Chládková J, Senkerík M, Havlínová Z, Krcmová I, Chládek J. Alveolar concentration and bronchial flux of nitric oxide: two linear modeling methods evaluated in children and adolescents with allergic rhinitis and atopic asthma. Pediatr Pulmonol ;47 (11 ): Petsky HL, Cates CJ, Li A, Kynaston JA, Turner C, Chang AB. Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults. Cochrane Database Syst Rev ;(4 ):CD Gibson PG. Using fractional exhaled nitric oxide to guide asthma therapy: design and methodological issues for ASthma TReatment ALgorithm studies. Clin Exp Allergy ;39 (4 ): Kharitonov SA, Yates D, Robbins RA, Logan-Sinclair R, Shinebourne EA, Barnes PJ. Increased nitric oxide in exhaled air of asthmatic patients. Lancet ;343 (8890 ): Paredi P, Kharitonov SA, Leak D, et al. Exhaled ethane is elevated in cystic fibrosis and correlates with carbon monoxide levels and airway obstruction. Am J Respir Crit Care Med ;161 (4 ): Kharitonov SA, Barnes PJ. Clinical aspects of exhaled nitric oxide. Eur Respir J ;16 (4 ): Brindicci C, Ito K, Barnes PJ, Kharitonov SA. Differential flow analysis of exhaled nitric oxide in patients with asthma of differing severity. Chest ;131 (5 ): Grasemann H, Ratjen F. Nitric oxide and L-arginine deficiency in cystic fibrosis. Curr Pharm Des ;18 (5 ): journal.publications.chestnet.org CHEST / 145 / 1 / JANUARY
Exhalation flow and pressure-controlled reservoir collection of exhaled nitric oxide for remote and delayed analysis
Thorax 998;5:775 779 775 Department of Thoracic Medicine, Imperial College School of Medicine at the National Heart and Lung Institute, Dovehouse Street, London SW 6LY, UK P Paredi S Loukides S A Kharitonov
More informationInhaled fluticasone decreases bronchial but not alveolar nitric oxide output in asthma
Eur Respir J 21; 18: 635 639 Printed in UK all rights reserved Copyright #ERS Journals Ltd 21 European Respiratory Journal ISSN 93-1936 Inhaled fluticasone decreases bronchial but not alveolar nitric oxide
More informationEffects of inhaled versus systemic corticosteroids on exhaled nitric oxide in severe acute asthma
Respiratory Medicine (2009) 103, 614e620 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed Effects of inhaled versus systemic corticosteroids on exhaled nitric oxide in
More informationComparison of exhaled nitric oxide measurements between NIOX MINO â electrochemical and Ecomedics chemiluminescence analyzer
Respiratory Medicine (2008) 102, 1667e1671 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed SHORT COMMUNICATION Comparison of exhaled nitric oxide measurements between
More information10801 Sixth St, Rancho Cucamonga, CA Tel (909) Fax (909) Visit our web site at:
for the Diagnosis and Management of Asthma and Other Pulmonary Disorders IEHP Policy: Based on a review of the currently available literature, there is insufficient evidence to support the use of FE NO
More informationA diagnosis of asthma is made on the basis of compatible
383 ASTHMA Exhaled nitric oxide in the diagnosis of asthma: comparison with bronchial provocation tests N Berkman, A Avital, R Breuer, E Bardach, C Springer, S Godfrey... See end of article for authors
More informationA simple technique to characterize proximal and peripheral nitric oxide exchange using constant flow exhalations and an axial diffusion model
J Appl Physiol 102: 417 425, 2007. First published August 3, 2006; doi:10.1152/japplphysiol.00533.2006. Innovative Methodology A simple technique to characterize proximal and peripheral nitric oxide exchange
More informationAssessment of a rapid liquid based cytology method for measuring sputum cell counts
Assessment of a rapid liquid based cytology method for measuring sputum cell counts Martin MJ, Lee H, Meakin G, Green A, Simms RL, Reynolds C, Winters S*, Shaw DE, Soomro I*, Harrison TW The Asthma Centre
More informationImportance of fractional exhaled nitric oxide in diagnosis of bronchiectasis accompanied with bronchial asthma
Original Article Importance of fractional exhaled nitric oxide in diagnosis of bronchiectasis accompanied with bronchial asthma Feng-Jia Chen, Huai Liao, Xin-Yan Huang, Can-Mao Xie Department of Respiratory
More informationMEDICAL POLICY. Proprietary Information of YourCare Health Plan
MEDICAL POLICY PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationAlveolar and Bronchial Nitric Oxide Output in Healthy Children
43:1242 1248 (2008) Alveolar and Bronchial Nitric Oxide Output in Healthy Children Anna Sepponen, MD, 1,2 Lauri Lehtimäki, MD, 1,2,3 Heini Huhtala, MSc, 4 Minna Kaila, MD, 5,6 Hannu Kankaanranta, MD, 1,2,7
More informationNG80. Asthma: diagnosis, monitoring and chronic asthma management (NG80)
Asthma: diagnosis, monitoring and chronic asthma management (NG80) NG80 NICE has checked the use of its content in this product and the sponsor has had no influence on the content of this booklet. NICE
More informationCentral and Peripheral Airway Sites of Nitric Oxide Gas Exchange in COPD
CHEST Central and Peripheral Airway Sites of Nitric Oxide Gas Exchange in COPD Arthur F. Gelb, MD, FCCP ; Colleen Flynn Taylor, MA ; Anita Krishnan, MD ; Christine Fraser, RCP, CPFT ; Chris M. Shinar,
More informationThis is a cross-sectional analysis of the National Health and Nutrition Examination
SUPPLEMENTAL METHODS Study Design and Setting This is a cross-sectional analysis of the National Health and Nutrition Examination Survey (NHANES) data 2007-2008, 2009-2010, and 2011-2012. The NHANES is
More informationCentral and peripheral airway/alveolar sites of exhaled nitric oxide in acute asthma
1 Pulmonary Division, Department of Medicine, Lakewood Regional Medical Center, and Geffen School of Medicine, University of California at Los Angeles Medical Center, Lakewood, California, USA 2 Department
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: exhaled_nitric_oxide_measurement 2/2009 3/2018 3/2019 3/2018 Description of Procedure or Service Asthma is
More informationClinical Policy: Fractional Exhaled Nitric Oxide Reference Number: CP.MP.103
Clinical Policy: Reference Number: CP.MP.103 Effective Date: 01/16 Last Review Date: 01/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and
More informationAcinar effect of inhaled steroids evidenced by exhaled nitric oxide
Acinar effect of inhaled steroids evidenced by exhaled nitric oxide Alain Van Muylem, PhD, Yannick Kerckx, PhD, and Alain Michils, PhD Brussels, Belgium Background: The effects of inhaled corticosteroids
More informationExhaled Nitric Oxide: An Adjunctive Tool in the Diagnosis and Management of Asthma
Exhaled Nitric Oxide: An Adjunctive Tool in the Diagnosis and Management of Asthma Jason Debley, MD, MPH Assistant Professor, Pediatrics Division of Pulmonary Medicine University of Washington School of
More informationMEDICAL POLICY. Proprietary Information of Excellus Health Plan, Inc. A nonprofit independent licensee of the BlueCross BlueShield Association
MEDICAL POLICY SUBJECT: MEASUREMENT OF EXHALED MARKERS OF AIRWAY INFLAMMATION IN PATIENTS WITH ASTHMA POLICY NUMBER: 2.01.41 CATEGORY: Technology Assessment EFFECTIVE DATE: 04/15/04 REVISED DATE: 02/17/05,
More informationAlveolar nitric oxide and asthma control in mild untreated asthma
Alveolar nitric oxide and asthma control in mild untreated asthma Nicola Scichilone, MD, Salvatore Battaglia, MD, Salvatore Taormina, PhD, Viviana Modica, PhD, Elena Pozzecco, PhD, and Vincenzo Bellia,
More informationASTHMA TREATMENT EFFICACY ASSESSMENT BY FeNO MEASUREMENT
Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 5 (54) No. 2-2012 ASTHMA TREATMENT EFFICACY ASSESSMENT BY FeNO MEASUREMENT Dana ALEXANDRESCU 1 Abstract: The author of
More informationAirway nitric oxide release is reduced after PBS inhalation in asthma
J Appl Physiol 102: 1028 1033, 2007. First published November 16, 2006; doi:10.1152/japplphysiol.01012.2006. Airway nitric oxide release is reduced after PBS inhalation in asthma Hye-Won Shin, 1 David
More informationAsthma is characterized by an inflammation of. Increase in Alveolar Nitric Oxide in the Presence of Symptoms in Childhood Asthma*
Increase in Alveolar Nitric Oxide in the Presence of Symptoms in Childhood Asthma* Bruno Mahut, MD; Christophe Delacourt, MD, PhD; Françoise Zerah-Lancner, MD; Jacques De Blic, MD; Alain Harf, MD, PhD;
More informationThe FDA Critical Path Initiative
The FDA Critical Path Initiative Clinical Considerations for Demonstration of Dose-response for Inhaled Corticosteroids - Exhaled Nitric Oxide Model Badrul A. Chowdhury, MD, PhD Director Division of Pulmonary
More informationRole of Spirometry and Exhaled Nitric Oxide To Predict Exacerbations in Treated Asthmatics*
Original Research ASTHMA Role of Spirometry and Exhaled Nitric Oxide To Predict Exacerbations in Treated Asthmatics* Arthur F. Gelb, MD, FCCP; Colleen Flynn Taylor, MA; Chris M. Shinar, PharmD; Carlos
More informationClinical Policy Title: Exhaled nitric oxide for diagnosis of lung disease
Clinical Policy Title: Exhaled nitric oxide for diagnosis of lung disease Clinical Policy Number: 07.01.04 Effective Date: June 1, 2014 Initial Review Date: February 19, 2014 Most Recent Review Date: November
More informationEvaluation of Exhaled Nitric Oxide in Schoolchildren at Different Exhalation Flow Rates
0031-3998/02/5203-0393 PEDIATRIC RESEARCH Vol. 52, No. 3, 2002 Copyright 2002 International Pediatric Research Foundation, Inc. Printed in U.S.A. Evaluation of Exhaled Nitric Oxide in Schoolchildren at
More informationFlow-independent nitric oxide exchange parameters in healthy adults
J Appl Physiol 91: 2173 2181, 2001. Flow-independent nitric oxide exchange parameters in healthy adults HYE-WON SHIN, 1 CHRISTINE M. ROSE-GOTTRON, 5 FEDERICO PEREZ, 1 DAN M. COOPER, 3,5 ARCHIE F. WILSON,
More informationExhaled nitric oxide measurements with dynamic flow restriction in children aged 4 8 yrs
Eur Respir J 2002; 20: 919 924 DOI: 10.1183/09031936.02.01282002 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2002 European Respiratory Journal ISSN 0903-1936 Exhaled nitric oxide measurements
More informationOutline FEF Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications?
Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications? Fernando Holguin MD MPH Director, Asthma Clinical & Research Program Center for lungs and Breathing University of Colorado
More informationMedical Coverage Policy Measurement of Exhaled Nitric Oxide and Exhaled Breath Condensate in the Diagnosis and Management of Respiratory Disorders
Medical Coverage Policy Measurement of Exhaled Nitric Oxide and Exhaled Breath Condensate in the Diagnosis and Management of Respiratory Disorders EFFECTIVE DATE: 03 03 2015 POLICY LAST UPDATED: 10 16
More informationExpired Nitric Oxide and Airway Obstruction in Asthma Patients with an Acute Exacerbation
Expired Nitric Oxide and Airway Obstruction in Asthma Patients with an Acute Exacerbation SCOTT E. CRATER, EDWARD J. PETERS, MARCUS L. MARTIN, ANDREW W. MURPHY, and THOMAS A. E. PLATTS-MILLS Asthma and
More informationDo current treatment protocols adequately prevent airway remodeling in children with mild intermittent asthma?
Respiratory Medicine (2006) 100, 458 462 Do current treatment protocols adequately prevent airway remodeling in children with mild intermittent asthma? Haim S. Bibi a,, David Feigenbaum a, Mariana Hessen
More informationClinical Policy Title: Exhaled nitric oxide for diagnosis of lung disease
Clinical Policy Title: Exhaled nitric oxide for diagnosis of lung disease Clinical Policy Number: 07.01.04 Effective Date: June 1, 2014 Initial Review Date: February 19, 2014 Most Recent Review Date: November
More informationComparison of 2 Methods to Correct for Peripheral Nitric Oxide Exchange in the Lungs
Correction for Alveolar Nitric Oxide ORIGINAL ARTICLE Comparison of Methods to Correct for Peripheral Nitric Oxide Exchange in the Lungs L Prieto, 1 V López, D Barato, J Marin 1 1 Universidad de Valencia,
More informationIncreased alveolar nitric oxide in early systemic sclerosis
Increased alveolar nitric oxide in early systemic sclerosis D.M. Wuttge 1, G. Bozovic 2, R. Hesselstrand 1, D. Aronsson 3, L. Bjermer 3, A. Scheja 1, E. Tufvesson 3 1 Department of Clinical Sciences, Lund,
More informationWhich asthma patient has allergic airway inflammation?
Which asthma patient has allergic airway inflammation? C o n t r o l l i n g A l l e r g i c A s t h m a Several underlying diseases can present symptoms similar to asthma. Therefore, a correct diagnos
More informationVALIDATION OF CONTINUOUS GLUCOSE MONITORING IN CHILDREN AND ADOLESCENTS WITH CYSTIC FIBROSIS - A PROSPECTIVE COHORT STUDY
Diabetes Care Publish Ahead of Print, published online March 11, 2009 Validation of CGM in Children with CF VALIDATION OF CONTINUOUS GLUCOSE MONITORING IN CHILDREN AND ADOLESCENTS WITH CYSTIC FIBROSIS
More informationEstimation of Parameters in the Two-Compartment Model for Exhaled Nitric Oxide
Estimation of Parameters in the Two-Compartment Model for Exhaled Nitric Oxide Sandrah P. Eckel 1 *, William S. Linn 1, Kiros Berhane 1, Edward B. Rappaport 1, Muhammad T. Salam 1, Yue Zhang 2, Frank D.
More informationKey words: asthma; dyspnea; exercise-induced bronchoconstriction; nitric oxide
Exhaled Nitric Oxide as a Predictor of Exercise-Induced Bronchoconstriction* Samy M. ElHalawani, DO; Nam T. Ly, MD; Richard T. Mahon, MD; and Dennis E. Amundson, DO Introduction: Exercise-induced bronchoconstriction
More informationDetermination of fractional exhaled nitric oxide (FENO) reference values in healthy Thai population
Asian Pacific Journal of Allergy and Immunology ORIGINAL ARTICLE Determination of fractional exhaled nitric oxide (FENO) reference values in healthy Thai population Yiwa Suksawat, Punchama Pacharn, Orathai
More informationOptimal Assessment of Asthma Control in Clinical Practice: Is there a role for biomarkers?
Disclosures: Optimal Assessment of Asthma Control in Clinical Practice: Is there a role for biomarkers? Stanley Fineman, MD Past-President, American College of Allergy, Asthma & Immunology Adjunct Associate
More informationToday's presentation will focus on... A major health problem. Asthma. A new exciting Biomarker. Exhaled Nitric Oxide
Today's presentation will focus on... A major health problem Asthma A new exciting Biomarker Exhaled Nitric Oxide An attractive life science business Aerocrine AB Asthma is a major global health problem
More informationA new and more accurate technique to characterize airway nitric oxide using different breath-hold times
A new and more accurate technique to characterize airway nitric oxide using different breath-hold times Hye-Won Shin, Peter Condorelli and Steven C. George Journal of Applied Physiology 98:1869-1877, 2005.
More informationBasic approach to PFT interpretation. Dr. Giulio Dominelli BSc, MD, FRCPC Kelowna Respiratory and Allergy Clinic
Basic approach to PFT interpretation Dr. Giulio Dominelli BSc, MD, FRCPC Kelowna Respiratory and Allergy Clinic Disclosures Received honorarium from Astra Zeneca for education presentations Tasked Asked
More informationExhaled Nitric Oxide and Exhaled Breath Condensate in the Management of Respiratory Disorders
Medical Coverage Policy Effective Date... 2/15/2018 Next Review Date... 2/15/2019 Coverage Policy Number... 0439 Exhaled Nitric Oxide and Exhaled Breath Condensate in the Management of Respiratory Disorders
More informationPredicting response to triamcinolone in severe asthma by machine learning: solving the Enigma
Page 1 of 5 Predicting response to triamcinolone in severe asthma by machine learning: solving the Enigma Kian Fan Chung National Heart & Lung Institute, Imperial College London & Royal Brompton and Harefield
More informationExhaled nitric oxide levels in asthma: Personal best versus reference values
Exhaled nitric oxide levels in asthma: Personal best versus reference values Andrew D. Smith, MRCP(UK), Jan O. Cowan, and D. Robin Taylor, MD Dunedin, New Zealand Background: Factors affecting the fraction
More informationOffice Based Spirometry
Osteopathic Family Physician (2014)1, 14-18 Scott Klosterman, DO; Woodson Crenshaw, OMS4 Spartanburg Regional Family Medicine Residency Program; Edward Via College of Osteopathic Medicine - Virginia Campus
More information#1 cause of school absenteeism in children 13 million missed days annually
Asthma Update 2013 Jennifer W. McCallister, MD, FACP, FCCP Associate Professor Pulmonary & Critical Care Medicine The Ohio State University Wexner Medical Center Disclosures None 2 Objectives Review burden
More informationNiche News August 2017 August 2017
Niche News August 2017 August 2017 In This Issue Greetings! Introducing the new EasyOne Air Spirometer LiteAire Spacer - Get Better Pricing with Bulk Buy FeNO "Value Proposition" White Paper EasyOne Pro
More informationInhaled and systemic corticosteroid response in severe asthma assessed by alveolar nitric oxide: a randomized crossover pilot study of add-on therapy
British Journal of Clinical Pharmacology DOI:1.1111/j.1365-2125.212.4319.x Inhaled and systemic corticosteroid response in severe asthma assessed by alveolar nitric oxide: a randomized crossover pilot
More informationPULMONARY FUNCTION TESTING. Purposes of Pulmonary Tests. General Categories of Lung Diseases. Types of PF Tests
PULMONARY FUNCTION TESTING Wyka Chapter 13 Various AARC Clinical Practice Guidelines Purposes of Pulmonary Tests Is lung disease present? If so, is it reversible? If so, what type of lung disease is present?
More informationBiomarker-based corticosteroid adjustment in severe asthma: a modified Delphi consensus
ORIGINAL RESEARCH LETTER Biomarker-based corticosteroid adjustment in severe asthma: a modified Delphi consensus To the Editor: Asthma is managed using step-wise adjustment of corticosteroid therapy to
More informationcompare patients preferences and costs for asthma treatment regimens targeting three
APPENDIX I ADDITIONAL METHODS Trial design The Accurate trial lasted from September 2009 until January 2012 and was designed to compare patients preferences and costs for asthma treatment regimens targeting
More informationExhaled Nitric Oxide and Exhaled Breath Condensate ph in Severe Refractory Asthma
CHEST Exhaled Nitric Oxide and Exhaled Breath Condensate ph in Severe Refractory Asthma Original Research Eleni Tseliou, MD ; Vasiliki Bessa, MD ; Georgios Hillas, MD ; Vasiliki Delimpoura, MD ; Georgia
More informationExhaled Nitric Oxide after 2 -agonist Inhalation and Spirometry in Asthma
Exhaled Nitric Oxide after 2 -agonist Inhalation and Spirometry in Asthma PHILIP E. SILKOFF, SUGURU WAKITA, JOSE CHATKIN, KHALIL ANSARIN, CARLOS GUTIERREZ, MARLOVA CARAMORI, PATRICIA MCCLEAN, ARTHUR S.
More informationMeenu Singh, Joseph L. Mathew, Prabhjot Malhi, B.R. Srinivas and Lata Kumar
Comparison of Improvement in Quality of Life Score with Objective Parameters of Pulmonary Function in Indian Asthmatic Children Receiving Inhaled Corticosteroid Therapy Meenu Singh, Joseph L. Mathew, Prabhjot
More informationSponsor. Generic drug name. Trial indication(s) Protocol number. Protocol title. Clinical trial phase. Study Start/End Dates.
Sponsor Novartis Generic drug name Fluticasone propionate Trial indication(s) Moderate-severe bronchial asthma Protocol number CQAE397A2202 Protocol title A randomized open label study to assess the utility
More informationExhaled Biomarkers Asthma & COPD. AS Paul DM Seminar 30 March 07
Exhaled Biomarkers Asthma & COPD AS Paul DM Seminar 30 March 07 Introduction Diagnosis and course of COPD/Asthma Clinical information Pulmonary function tests Arterial blood gases Chest X-raysX No direct
More informationAn Elevated Bronchodilator Response Predicts Large Airway Inflammation in Mild Asthma
45:174 181 (2010) An Elevated Bronchodilator Response Predicts Large Airway Inflammation in Mild Asthma James L. Puckett, PhD, 1 Richard W.E. Taylor, BS, 1 Szu-Yun Leu, PhD, 2 Olga L. Guijon, MD, 3 Anna
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/61041 holds various files of this Leiden University dissertation. Author: Thijs, W. Title: Obesity-related risk factors for impaired lung function Issue
More informationMedical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Measurement of Exhaled Nitric Oxide and Page 1 of 18 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Measurement of Exhaled Nitric Oxide and Exhaled Breath Condensate
More informationSpirometry: Introduction
Spirometry: Introduction Dr. Badri Paudel 1 2 GMC Spirometry Spirometry is a method of assessing lung function by measuring the volume of air the patient can expel from the lungs after a maximal expiration.
More informationChanges of exhaled nitric oxide during steroid treatment of childhood asthma
Eur Respir J 2002; 19: 1015 1019 DOI: 10.1183/09031936.02.01582001 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2002 European Respiratory Journal ISSN 0903-1936 Changes of exhaled nitric
More informationDefining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist
Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease
More informationAdenosine 5 0 -monophosphate increases levels of leukotrienes in breath condensate in asthma
Respiratory Medicine (2004) 98, 651 655 Adenosine 5 0 -monophosphate increases levels of leukotrienes in breath condensate in asthma E. Bucchioni, Z. Csoma, L. Allegra, K.F. Chung, P.J. Barnes, S.A. Kharitonov*
More informationRelationship between Methacholine Challenge Testing and exhaled Nitric Oxide in adult patients with suspected bronchial asthma
O R I G I N A L A R T I C L E S Eur Ann Allergy Clin Immunol Vol 46, N 3, 109-113, 2014 M. Giovannini, M. Valli, V. Ribuffo, R. Melara, G. Cappiello, E. Businarolo, A. Andreani Relationship between Methacholine
More informationC hronic obstructive pulmonary disease (COPD) is one of
589 RESPIRATORY INFECTIONS Time course of recovery of health status following an infective exacerbation of chronic bronchitis S Spencer, P W Jones for the GLOBE Study Group... Thorax 2003;58:589 593 See
More informationExhaled Nitric Oxide Today s Asthma Biomarker. Richard F. Lavi, MD FAAAAI FAAP
Exhaled Nitric Oxide Today s Asthma Biomarker Richard F. Lavi, MD FAAAAI FAAP Objectives Describe exhaled nitric oxide physiology and pathophysiology Review the current literature regarding exhaled nitric
More informationCorrelation of exhaled carbon monoxide and nitric oxide with airflow obstruction in asthma and chronic obstructive pulmonary disease patients
Available online at www.scholarsresearchlibrary.com Annals of Biological Research, 212, 3 (4):1672-1678 (http://scholarsresearchlibrary.com/archive.html) ISSN 976-1233 CODEN (USA): ABRNBW Correlation of
More informationCASE REPORT INTRODUCTION
Allergology International. ; : - DOI: 10.2332 allergolint.10-cr-0251 CASE REPORT Centrilobular Opacities in the Asthmatic Lung Successfully Treated with Inhaled Ciclesonide and Tiotropium: With Assessment
More informationDomiciliary diurnal variation of exhaled nitric oxide fraction for asthma control
ORIGINAL ARTICLE ASTHMA Domiciliary diurnal variation of exhaled nitric oxide fraction for asthma control Junpei Saito, David Gibeon, Patricia Macedo, Andrew Menzies-Gow, Pankaj K. Bhavsar and Kian Fan
More information8-ISOPROSTANE IN NASALLY EXHALED BREATH CONDENSATE IN DIFFERENT PEDIATRIC LUNG DISEASES
January 31, 2007 EU RO PE AN JOUR NAL OF MED I CAL RE SEARCH 21 Eur J Med Res (2007) 12: 21-25 I. Holzapfel Publishers 2007 8-ISOPROSTANE IN NASALLY EXHALED BREATH CONDENSATE IN DIFFERENT PEDIATRIC LUNG
More informationLife-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton
Life-long asthma and its relationship to COPD Stephen T Holgate School of Medicine University of Southampton Definitions COPD is a preventable and treatable disease with some significant extrapulmonary
More informationDifferences in Exhaled Nitric Oxide in Non- and Mono- or Polysensitised Allergic Children with Asthma Bronchiale
30 The Open Pediatric Medicine Journal, 2008, 2, 30-34 Open Access Differences in Exhaled Nitric Oxide in Non- and Mono- or Polysensitised Allergic Children with Asthma Bronchiale Leonie Korsch, Annette
More informationSpirometry and Flow Volume Measurements
Spirometry and Flow Volume Measurements Standards & Guidelines December 1998 To serve the public and guide the medical profession Revision Dates: December 1998 Approval Date: June 1998 Originating Committee:
More informationChallenges in Meeting International Requirements for Clinical Bioequivalence of Inhaled Drug Products
Challenges in Meeting International Requirements for Clinical Bioequivalence of Inhaled Drug Products Tushar Shah, M.D. Sr. VP, Global Respiratory Research and Development TEVA Pharmaceuticals 1 Presentation
More informationNIOX VERO. For assessment and management of airway inflammation
NIOX VERO For assessment and management of airway inflammation NIOX VERO NIOX VERO is a point-of-care device for assessing airway inflammation in patients with respiratory problems such as asthma. NIOX
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationCOPD and Asthma: Similarities and differences Prof. Peter Barnes
and Asthma: Similarities and Differences and Asthma: 1 Imperial College Peter Barnes FRS, FMedSci, National Heart & Lung Institute Imperial College, London, UK p.j.barnes@imperial.ac.uk Royal Brompton
More informationExhaled markers of inflammatory lung diseases: ready for routine monitoring?
Review article Peer reviewed article SWISS MED WKLY 2004;134:175 192 www.smw.ch 175 Exhaled markers of inflammatory lung diseases: ready for routine monitoring? Sergei A. Kharitonov National Heart and
More informationKEY WORDS airflow limitation, airway hyperresponsiveness, airway inflammation, airway lability, peak expiratory flow rate
Allergology International. 2013;62:343-349 DOI: 10.2332 allergolint.13-oa-0543 ORIGINAL ARTICLE Stratifying a Risk for an Increased Variation of Airway Caliber among the Clinically Stable Asthma Atsushi
More informationDevelopment of a self-reported Chronic Respiratory Questionnaire (CRQ-SR)
954 Department of Respiratory Medicine, University Hospitals of Leicester, Glenfield Hospital, Leicester LE3 9QP, UK J E A Williams S J Singh L Sewell M D L Morgan Department of Clinical Epidemiology and
More informationSingle-exhalation profiles of NO and CO 2 in humans: effect of dynamically changing flow rate
Single-exhalation profiles of NO and CO 2 in humans: effect of dynamically changing flow rate NIKOLAOS M. TSOUKIAS, 1 ZIAD TANNOUS, 2 ARCHIE F. WILSON, 2 AND STEVEN C. GEORGE 1 1 Department of Chemical
More informationOriginal Contributions
Original Contributions Comparison of a New Desktop Spirometer (Spirospec) with a Laboratory Spirometer in a Respiratory Out-Patient Clinic François Swart, Macé M Schuurmans MD, Johannes C Heydenreich,
More informationMeasurement of Fractional Exhaled Nitric Oxide in Stable Bronchiectasis
http://dx.doi.org/10.4046/trd.2013.74.1.7 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2013;74:7-14 CopyrightC2013. The Korean Academy of Tuberculosis and Respiratory Diseases. All rights
More informationSmall Airways Disease. Respiratory Function In Small Airways And Asthma. Pathophysiologic Changes in the Small Airways of Asthma Patients
Small Airways Disease Respiratory Function In Small Airways And Relevant Questions On Small Airway Involvement In How can small airway disease be defined? What is the link between small airway abnormalities
More informationDiagnostics guidance Published: 2 April 2014 nice.org.uk/guidance/dg12
Measuring fractional exhaled nitric oxide concentration in asthma: NIOX MINO, NIOX VERO and NObreath Diagnostics guidance Published: 2 April 2014 nice.org.uk/guidance/dg12 NICE 2017. All rights reserved.
More informationAssessment of accuracy and applicability of a new electronic peak flow meter and asthma monitor
Eur Respir J 18; 12: 45 42 DOI: 18/1.8.5 Printed in UK - all rights reserved Copyright ERS Journals Ltd 18 European Respiratory Journal ISSN - 1 Assessment of accuracy and applicability of a new electronic
More informationMaximal expiratory flow rates (MEFR) measured. Maximal Inspiratory Flow Rates in Patients With COPD*
Maximal Inspiratory Flow Rates in Patients With COPD* Dan Stănescu, MD, PhD; Claude Veriter, MA; and Karel P. Van de Woestijne, MD, PhD Objectives: To assess the relevance of maximal inspiratory flow rates
More informationDifferential diagnosis
Differential diagnosis The onset of COPD is insidious. Pathological changes may begin years before symptoms appear. The major differential diagnosis is asthma, and in some cases, a clear distinction between
More informationDiagnosing Asthma Comparisons between Exhaled Nitric Oxide Measurements and Conventional Tests
Diagnosing Asthma Comparisons between Exhaled Nitric Oxide Measurements and Conventional Tests Andrew D. Smith, Jan O. Cowan, Sue Filsell, Chris McLachlan, Gabrielle Monti-Sheehan, Pamela Jackson, and
More informationDo patients with sickle cell disease have asthma?
Do patients with sickle cell disease have asthma? Anne Greenough Faculty of Life Sciences and Medicine King s College, London MRC & Asthma UK Centre in Allergic Mechanisms of Asthma Sickle Cell Disease
More informationChapter 10. The Respiratory System Exchange of Gases. Copyright 2009 Pearson Education, Inc.
Chapter 10 The Respiratory System Exchange of Gases http://www.encognitive.com/images/respiratory-system.jpg Human Respiratory System UPPER RESPIRATORY TRACT LOWER RESPIRATORY TRACT Nose Passageway for
More informationAirway eosinophils in older teenagers with outgrown preschool wheeze: a pilot study
LETTERS Airway eosinophils in older teenagers with outgrown preschool wheeze: a pilot study To the Editor, Preschool wheezing affects one-third of all children growing up in the UK []. It varies in clinical
More informationClinical Benefits of FeNO Monitoring in Asthma RYAN BURTON, MS, RPFT
Clinical Benefits of FeNO Monitoring in Asthma RYAN BURTON, MS, RPFT Disclosures I am an employee of Circassia Pharmaceuticals. Objectives Nitric Oxide Inflammation in Asthma Phenotyping Personalized Medicine
More informationElevated nitrite in breath condensates of children with respiratory disease
Eur Respir J 2002; 19: 487 491 DOI: 10.1183/09031936.02.00101202 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2002 European Respiratory Journal ISSN 0903-1936 Elevated nitrite in breath
More information